Tagged: Cardiology

Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the BIOSOLVE-II first-in-man trial at 5 years

Publication date: Available online 22 July 2021 Source: Cardiovascular Revascularization Medicine Author(s): Michael Haude, Ralph Toelg, Pedro Alves Lemos, Evald Høj Christiansen, Alexandre Abizaid, Clemens von Birgelen, Franz-Josef Neumann, William Wijns, Hüseyin Ince, Christoph Kaiser, Soo Teik Lim, Javier Escaned, Eric Eeckhout, Hector M. Garcia-Garcia, Ron Waksman

Impact of chronic kidney disease in chronic total occlusion management and clinical outcomes

Publication date: Available online 21 July 2021Source: Cardiovascular Revascularization MedicineAuthor(s): Eduardo Flores-Umanzor, Pedro Cepas-Guillen, Luis Álvarez-Contreras, Guillem Caldentey, Leticia Castrillo-Golvano, Andrea Fernandez-Valledor, Anthony Salazar-Rodriguez, Victor Arévalos, Rami Gabani, Ander Regueiro, Salvatore Brugaletta, Mercè Roqué, Xavier Freixa, Victoria Martín-Yuste, Manel Sabaté

The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure

Type 2 diabetes (T2D) is an established risk factor for ischemic cardiovascular disease (CVD) and heart failure (HF).(1) The risks of ischemic CVD and HF are increased with albuminuria and/or impaired kidney function. Although in recent decades cardiovascular outcomes have improved for adults with or without T2D, reducing the burden associated with HF by treating classical cardiovascular risk factors has proven to be difficult and thus remains a major public health priority.(2) Accordingly, the introduction of sodium-glucose cotransporter (SGLT) 2 inhibitors offers promise to mitigate cardiorenal disease in people with or without T2D.

Cardio-ankle vascular index is associated with coronary plaque composition assessed with iMAP-intravascular ultrasound in patients with coronary artery disease

Acute coronary syndrome (ACS) mostly occurs owing to the rupture of vulnerable or high-risk plaques, which are characterized by the presence of a large necrotic core and a thin fibrous cap [1]. Although predicting patients with vulnerable plaques may be relevant to prognosis and optimal treatment choice, no simple, reliable, and noninvasive method has been established.

Enable Notifications    OK No thanks